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AND NEWBORN HEALTH 
COMMODITIES IN BANGLADESH
The UN Commission on Life-Saving Com-
modities for Women and Children aims 
to increase access to 13 commodities in 
50 countries. As part of this global effort, 
the Population Council conducted a land-
scape analysis in Bangladesh to review 
policies, guidelines, availability, and use 
of these commodities.  
The landscaping exercise had two objectives: 1) To 
provide a comprehensive description of maternal 
and newborn health (MNH) commodity issues 
from policy to point of care; and 2) To engage 
stakeholders in rolling out the UN Commission 
recommendations. 
Specifically, the goals of this study were to: 
• Engage with national leaders to determine 
national priorities and information gaps; 
• Examine policies and guidelines that impact the 
use of the 13 lifesaving commodities;
• Explore procurement mechanisms, 
manufacturing capacity, availability of quality 
assurance guidelines/policies, product packaging 
policies, distribution mechanisms, cost to end 
users, and financing; 
• Examine access to, and availability of, the 13 
lifesaving commodities in public facilities at the 
district, sub-district, and community levels, and in 
private drugstores;
• Assess stakeholders’ i nterest and participation 
in ensuring access to commodities; and
• Stimulate discussion to identify policies for 
increasing access and availability.
METHODS 
This landscape assessment 
exercise had three 
components: In-depth 
interviews, web searches, 
and site visits. Twenty one 
in-depth interviews with 
representatives from the 
Ministry of Health and 
Family Welfare (MoH&FW), 
professional associations, 
development partners, 
pharmaceuticals, and NGOs 
complemented the searches 
and provided greater detail. 
Online searches for drug 
manufacturers were 
conducted at http://www.
bddrugs.com/, and individual 
websites of pharmaceutical companies and the Directorate 
General of Drug Administration (DGDA) at http://www.dgda.
gov.bd. 
To validate the availability of the commodities, researchers 
visited public facilities and private drugstores at the district, 
sub-district, and community levels, and assessed which 
of the 13 commodities were available, which were out of 
stock, and how the drugs were stored (including humidity 
and temperature control/refrigeration) the day of the visit. 
Following data collection, policy makers, program 
managers, regulators, pharmaceutical industry 
representatives, and other stakeholders attended 
a workshop to share and discuss the assessment 
findings and identify priority activities to strengthen 
the implementation of the UN Commission’s 
recommendations. 
Another study opera-
tionalized and assessed 
the ability of community 
facility health providers 
to detect, prevent, and 
treat pre-eclampsia and 
eclampsia (PE/E), as well 
as administer a single 
loading dose of MgSO4 
before referral to second-
ary facilities. See accom-
panying “Operationalizing 
National Protocol for 
Preventing and Managing 
PE/E in Community Facil-
ities in Bangladesh.”  
2TABLE 1. BARRIERS AND IMPACT (GLOBAL)
Commodity Examples of key barriers Potential five-year impact
Maternal health commodities
1. Oxytocin - post-partum 
haemorrhage (PPH) Often poor quality
15,000 maternal lives saved 
2. Misoprostol - post-partum 
haemorrhage (PPH)
Not included in national essential 
medicines lists 
3. Magnesium sulphate (MgSO4) - 
severe pre-eclampsia and eclampsia Lack of demand by health workers 55,000 maternal lives saved 
Newborn health commodities 
4. Injectable antibiotics - newborn 
sepsis Poor compliance by health workers 1.22 million neonatal lives saved 
5. Antenatal corticosteroids (ANCs) - 
preterm respiratory distress syndrome Low awareness of product and impact 466,000 neonatal lives saved 
6. Chlorhexidine - newborn cord care Limited awareness and demand 422,000 neonatal lives saved 
7. Resuscitation devices - newborn 
asphyxia Requires trained health workers 336,000 neonatal lives saved 
Child health commodities 
8. Amoxicillin - pneumonia Limited availability of child-friendly product 1.56 million lives saved 
9. Oral rehydration salt (ORS) - 
diarrhea Poor understanding of products by 
mothers/caregivers 1.89 million lives saved 
10. Zinc - diarrhea
Reproductive health commodities 
11. Female condoms Low awareness among women and health workers 
Almost 230,000 maternal deaths 
averted 
12. Contraceptive implants - family 
planning/contraception High cost 
13. Emergency contraception Low awareness among women 
DISCLAIMER:  *The table above was adapted from the Commissioner’s Report from UN Commission on Life-Saving 
Commodities for Women and Children, September 2012. It provides estimates of how many lives could be saved if common 
barriers were overcome and equitable access achieved for 13 lifesaving commodities. The numbers presented are draft 
estimates meant to give a general overview of the barriers certain commodities face and the potential impact if these barriers 
were surmounted. These draft estimates are based on a systematic analysis approach. 
FINDINGS
Drug policies and guidelines
An important component of the National Drug Policy (NDP) 
is to ensure quality drugs are available and affordable. 
The policy also requires that quality assurance measures 
occur during manufacturing, transit, and storage, along 
with testing at different time points before it reaches the 
end user. All drugs, medicines, and other commodities 
in final dosage forms that are manufactured, imported, 
distributed, marketed, or consumed in the country must 
be registered with the DGDA in the specific dosages and 
strengths recommended by the Drug Control Committee.
The landscaping exercise found all 13 lifesaving 
commodities, except female condoms, are registered but 
not available in the specific dosages needed for particular 
MNH conditions or indications. For example, MgSO4 is not 
available as a single loading dose in community facilities. 
Additionally, some drugs were out of stock and shortages 
were reported. See Table 1 for more information. 
Interviews with policy makers and program mangers 
suggest those responsible for implementing MNH policies 
and services were unaware of specific commodity policies, 
the UN Commission report, and its recommendations. 
There appears to be a lack of coordination between 
drugstore keepers and providers. As a result, providers 
are not aware of which drugs and commodities are 
available in facility stores. Also, many providers reported 
not being able to estimate the consumption rate of drugs 
and commodities in their facilities due to a lack of data. 
Quality control and quality assurance 
The NDP requires that each pharmaceutical company 
have quality control and quality assurance systems, 
which monitor the entire manufacturing process from 
the acquisition of raw materials to its conversion into a 
finished product. It also requires that all pharmaceutical 
companies have documented standard operating 
procedures based on World Health Organization 
recommended guidelines for each product.  
Findings from interviews with drug authorities and 
pharmaceutical representatives reveal drug testing 
laboratories have limited manpower and logistics capacity. 
These quality control mechanisms can only test 30% of 
the 3,500 products developed each year. 
Logistics and ordering of supplies
The MoH&FW follows the World Bank procedure for 
procuring drugs and commodities through an open 
bidding process. The lowest bidder gets the order if 
they have requisite qualifications and can fulfill the 
specifications required in the tender. By this process, 
MoH&FW gets the lowest price.
There are several domestic pharmaceutical manufacturers 
producing most of the 13 commodities. The DGDA regulates 
the prices of local products, and without its approval no 
pharmaceutical company can fix the price of drugs or 
commodities. 
Pharmaceutical manufacturers generally teach correct 
storage practices to distributors, but not to drugstores, and 
as a result, a knowledge gap for proper storage remains in 
community drugstores. Currently, there is no public private 
partnership for pharmaceutical products.  
Usually, drugs and commodities are ordered at the national 
level, stored at central warehouses, and then distributed to 
districts and facilities. At the sub-district level, there is no 
scope for local procurement. 
In facilities, most respondents were unaware of the 
quality control and quality assurance guidelines. However, 
pharmaceutical company representatives mentioned that 
the DGDA quality assurance guidelines required them to 
have their own standard operating procedures. They also 
said end users are unwilling to pay for the drugs. This 
low demand for oxytocin, misoprostol, MgSO4, antenatal 
corticosteroids, zinc, and emergency contraceptive pills 
serves as a disincentive to stock them. 
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Above: MNH drugs stored in a public facility. Below: Workshop partic-
ipants. Photos by Population Council. 
Private drugstores/pharmacies
Researchers visited 27 private drugstores and 
pharmacies at all levels to determine the availability of 
the drugs and commodities. Overall, the most available 
drugs were amoxicillin, zinc, and oral rehydration salts. 
However, oxytocin, misoprostol, and MgSO4 were less 
available. Almost all drug sellers reported low demand 
for them, as they require a doctor’s prescription and their 
volume of sales depended on the extent to which doctors 
prescribed them. Drugstore keepers explained that they 
lose money if the drugs expired on the shelf due to low 
sales, and so they do not stock them.  
Packaging of product 
Individual packaging for each of the 13 commodities 
is unavailable. Many of them are available in universal 
dosages, from which service providers must decide the 
amount given for specific MNH indications. For example, 
antibiotics for neonatal sepsis are available in various 
dose forms of drop, suspension, tablet, and injection in 
different concentrations. It is not specifically packaged 
for neonatal sepsis, but simply mentioned as one of the 
indications. 
Similarly, MgSO4 is available in solution, but in different 
concentrations. There is no separate packaging for a 
loading dose of 10 mg in a vial. Available forms are 
2.46 grams per 5 ml or 4 grams in per 100 ml vial, 
which means four vials are required as a loading dose in 
community facilities before referral. 
No drug is included in existing bundles, such as the 
delivery kit, but there are ongoing discussions about 
this. The prospect of separate packaging had enormous 
support from all respondents, as they felt separate 
packaging of appropriate doses would help with proper 
dosages for specific indications.  
Financing 
The government supplies all drugs and commodities 
for free to providers in facilities or during doorstep 
deliveries. However, in reality services and drugs at 
the facilities are not free of cost, and end users have 
considerable out of pocket expenses. They may have 
to pay informal service fees or purchase drugs from 
external sources.  
Drug sellers feel that health expenditures and out of 
pocket expenses in the market are within reach for 
most end users. They also said there must be a safety 
net provided for ultra-poor people. All respondents 
felt products should be included in conditional cash 
transfer coupons, vouchers, or other similar schemes, 
particularly the ongoing public sector maternal health 
voucher schemes.
RECOMMENDATIONS 
• Stronger advocacy with pharmaceutical companies to 
manufacture a single loading dose of MgSO4 solution;
• Essential drugs and commodities should be available in 
UH&FWCs, where normal vaginal deliveries are planned 
and conducted;
• Formation of a forum at the Directorate General of 
Family Planning (DGFP) to advocate access to, and use of, 
MNH drugs and commodities;
• Further initiatives that ensure drug quality, 
appropriateness of dosage, and reliable availability in the 
private and public spheres; and
• DGDA, DGFP, and Directorate General of Health Services 
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